{"title":"Everyone wants in, but with no ground rules, the biosimilar business remains elusive.","authors":"John Carroll","doi":"","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":89534,"journal":{"name":"Biotechnology healthcare","volume":"8 3","pages":"12-3"},"PeriodicalIF":0.0000,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278118/pdf/bh0803012.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biotechnology healthcare","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}